Dexamethasone vs Dexmedetomidine for iPACK + ACB in TKA
Eligible age
65–100 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This randomized, double-blind, controlled trial is designed to compare the analgesic efficacy and safety of perineural dexamethasone versus perineural dexmedetomidine as adjuvants to ropivacaine for ultrasound-guided interspace between the popliteal artery and the capsule of the posterior knee (iPACK) and adductor canal blocks in patients undergoing primary unilateral total knee arthroplasty (TKA). Elderly participants scheduled for elective TKA will be randomized into three parallel groups: ropivacaine alone (control), ropivacaine combined with perineural dexamethasone, or ropivacaine combined with perineural dexmedetomidine. The primary objective is to determine whether the addition of either adjuvant reduces postoperative opioid consumption compared with ropivacaine alone and to assess potential differences in analgesic efficacy between the two adjuvants. Secondary outcomes include pain intensity at rest and during mobilization, time to first rescue analgesia, quality of early functional recovery, and the incidence of adverse events, including postoperative nausea and vomiting, motor impairment, and hemodynamic instability.
Sponsor: Poznan University of Medical Sciences
You may qualify if…
- ✓ Age ≥ 65 years
- ✓ Scheduled for primary unilateral total knee arthroplasty under standardized anesthetic protocol
- ✓ ASA physical status II-III (or I-III, zależnie jak planujesz)
- ✓ Ability to understand the study procedures and provide written informed consent
You may not qualify if…
- ✕ Contraindications to peripheral nerve blocks (infection at injection site, coagulopathy, patient refusal)
- ✕ Known allergy or hypersensitivity to amide local anesthetics, dexamethasone or dexmedetomidine
- ✕ Chronic opioid therapy or opioid use \> 30 mg oral morphine equivalents per day in the last 3 months
- ✕ Severe hepatic or renal impairment
- ✕ Significant cognitive impairment, inability to cooperate with pain assessment
- ✕ Participation in another interventional trial affecting pain or analgesic consumption
Source: ClinicalTrials.gov · NCT07386600 · last updated 2026-02-04